Philip Ashton-Rickardt, Boston-based biotech leader, urges renewed commitment to resilience, learning, and innovation to tackle complex brain disorders.
BOSTON, MA / ACCESS Newswire / May 4, 2026 / Philip Ashton-Rickardt, Managing Director and Chief Scientific Officer at BE Therapeutics, is speaking out about the urgent need for stronger awareness, sustained effort, and innovation in the fight against neurodegenerative diseases such as ALS and multiple sclerosis.
With decades of experience across academia and biotech, Ashton-Rickardt is calling on scientists, entrepreneurs, and individuals alike to take a more active role in supporting progress in this space.
“Trying to create something new and important is what drives this work,” he says.
A Growing Global Challenge
Neurodegenerative diseases are a rising global health concern. According to the World Health Organization, neurological disorders are now the leading cause of disability worldwide. Conditions like Alzheimer’s, ALS, and Parkinson’s affect hundreds of millions of people, with cases expected to increase as populations age.
In the United States alone, nearly 6 million people are living with Alzheimer’s disease. That number is projected to double by 2050. ALS, while rarer, remains fatal in most cases within 2 to 5 years of diagnosis.
Despite these numbers, effective treatments remain limited.
“There are no easy answers,” Ashton-Rickardt says. “But that’s exactly why this work matters.”
From Science to Real-World Impact
Ashton-Rickardt has spent his career working at the intersection of science and application. From his early days in academia to founding biotech companies, his focus has remained consistent: turning research into real therapies.
He believes that progress depends not only on funding and research, but also on mindset.
“Resilience, flexibility, hard work, curiosity,” he says. “Those are the traits that move things forward.”
He also stresses the importance of continuous learning in a rapidly evolving field.
“Always learn,” he adds.
Why Awareness Still Matters
While scientific advances continue, Ashton-Rickardt notes that awareness and understanding among the broader public still lag behind.
Many people are not aware of how complex these diseases are, or how long it takes to develop new treatments. Clinical development can take over a decade and cost billions of dollars.
At the same time, early support-whether through education, advocacy, or personal engagement-can make a difference.
“Take one step at a time,” he says. “Progress builds from small actions.”
What Individuals Can Do
Ashton-Rickardt emphasizes that supporting innovation in neurodegenerative disease is not limited to scientists or investors. Individuals can play a role in meaningful ways:
-
Stay informed about neurological diseases and emerging treatments
-
Support credible research organizations and patient communities
-
Advocate for science education and innovation in local communities
-
Encourage curiosity and learning in the next generation
“Being authentic and trying to be yourself matters,” he says. “Everyone has a role to play in moving things forward.”
A Call for Long-Term Thinking
One of Ashton-Rickardt’s key messages is the need for patience and long-term commitment.
Breakthroughs in biotech do not happen overnight. They require years of effort, setbacks, and iteration.
“Think back to when things were worse,” he says. “Then take the next step.”
This mindset, he believes, is essential not just for scientists, but for anyone who wants to contribute to meaningful change.
The Future He’s Building Now
Ashton-Rickardt continues to lead efforts in developing engineered cell therapies aimed at treating brain disorders. While the science is complex, his message is simple.
Stay curious. Stay resilient. Keep building.
“I have my own standards,” he says. “And I’m always learning.”
About Philip Ashton-Rickardt
Philip Ashton-Rickardt is the Managing Director and Chief Scientific Officer at BE Therapeutics and a co-founder of Halyard Therapeutics. A Boston-based biotech leader, he has spent his career advancing immunology research and developing innovative cell therapies for neurodegenerative and immunological diseases. Previously, he served as Chief Scientific Officer at Sigilon Therapeutics, which was acquired by Eli Lilly, and founded Smith Therapeutics. Earlier in his career, he held academic leadership roles at Imperial College London and the University of Chicago.
Media Contact:
https://www.philipashton-rickardt.com
info@philipashton-rickardt.com
SOURCE: Philip Ashton-Rickardt
View the original press release on ACCESS Newswire
Media gallery
